Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Sep. 30, 2020		Sep. 30, 2019		Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 11,976	[1]	$ 10,331	[1]	$ 28,898	$ 28,807
General and administrative	8,998	[2]	4,163	[2]	18,662	5,748
Total operating expenses	20,974		14,494		47,560	34,555
Interest expense	0		249		0	249
Other income, net	(225)		(294)		(151)	(319)
Loss before provision for income taxes	(20,749)		(14,449)		(47,409)	(34,485)
Provision for income taxes	40		33		88	56
Net loss	$ (20,789)		$ (14,482)		$ (47,497)	$ (34,541)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.25)	[3]	$ (0.38)	[3]	$ (0.61)	$ (0.90)
Weighted-average common shares outstanding – basic and diluted	84,353,438	[3]	38,590,381	[3]	77,623,132	38,590,381

[1] Includes $68 and $176 of costs allocated from Roivant Sciences Ltd. for the three and six months ended September 30, 2020, respectively, and $1 and $152 of costs allocated from Roivant Sciences Ltd. for the three and six months ended September 30, 2019, respectively.

[2] Includes $173 and $337 of costs allocated from Roivant Sciences Ltd. for the three and six months ended September 30, 2020, respectively, and $270 and $514 of costs allocated from Roivant Sciences Ltd. for the three and six months ended September 30, 2019, respectively.

[3] Retroactively restated for the reverse recapitalization as described in Note 1.